9UA Stock Chart & Stats
€1.79
-€0.05(-3.50%)
At close: 4:00 PM EDT
€1.79
-€0.05(-3.50%)
Day’s Range― - ―
52-Week Range€1.22 - €5.00
Previous CloseN/A
Volume0.00
Average Volume (3M)628.00
Market Cap
€144.76M
Enterprise Value€155.34M
Total Cash (Recent Filing)€86.93M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Nov 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding107,616,410
10 Day Avg. Volume1,426
30 Day Avg. Volume628
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)159.85
Price to Sales (P/S)0.00
P/FCF Ratio-28.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.95Price Target Upside400.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageNear-zero debt limits fixed financial obligations and preserves flexibility while NervGen funds clinical development. The improved asset base also indicates stronger capitalization than in prior periods, giving the company a more resilient platform for advancing its pipeline without substantial interest burdens.
Stronger Cash PositionThe sharp increase in cash provides additional support for ongoing clinical trials and corporate operations over the coming quarters. Although funding needs remain significant, a larger cash balance can reduce immediate financing pressure and allow management to maintain development activity.
Audit OversightThe orderly auditor transition, together with audit committee and board approval and the absence of prior modified opinions or reportable events, provides some evidence of continuing formal oversight. This may help support regulatory reporting and governance as the company advances its programs.
Bears Say
Pre-Revenue LossesNervGen has no recurring product revenue to offset its development expenses, while losses have widened materially. This lack of operating income leaves financial performance dependent on future financing, partnerships, or successful commercialization of pipeline assets rather than an established revenue base.
Accelerating Cash BurnPersistently negative and worsening operating cash flow shows that the business is consuming capital as it develops its therapies. Continued cash burn can increase reliance on external funding and constrain strategic flexibility, particularly if clinical or regulatory spending remains elevated.
Financial RestatementsPlanned restatements for stock-option and warrant-liability valuation errors expose weaknesses in financial reporting controls and reduce confidence in previously published results. Although the errors are non-cash and do not affect liquidity, remediation can create governance, reporting, and investor-relations burdens.
NervGen Pharma News
9UA FAQ
What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was €1.22 and its highest was €5.00 in the past 12 months.
What is NervGen Pharma’s market cap?
NervGen Pharma’s market cap is €144.76M.
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s upcoming earnings report date is Nov 12, 2026 which is in 13 days.
How were NervGen Pharma’s earnings last quarter?
NervGen Pharma released its earnings results on Aug 13, 2026. The company reported -€0.237 earnings per share for the quarter, missing the consensus estimate of -€0.054 by -€0.182.
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Undervalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate is -0.09.
How many shares outstanding does NervGen Pharma have?
NervGen Pharma has 107,616,410 shares outstanding.
What happened to NervGen Pharma’s price movement after its last earnings report?
NervGen Pharma reported an EPS of -€0.237 in its last earnings report, missing expectations of -€0.054. Following the earnings report the stock price went up 2.837%.
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in DE:9UA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NervGen Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€8.95 (400.08% Upside)
€8.95 (400.08% Upside)
Blogger Sentiment
Bullish
DE:9UA Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.35%
12-Months-Change
Fundamentals
Return on Equity
-1156.14%
Trailing 12-Months
Asset Growth
412.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NervGen Pharma
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
9UA Stock 12 Month Forecast
Average Price Target
€8.95
▲(400.08% Upside)
Technical Analysis
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―